1-3 of 3
Karen L Manion
Close
Sort by
Journal Articles

Low Dose Subcutaneous Alemtuzumab and Prophylactic Donor Lymphocyte Infusion Results in Favorable Outcomes for High Risk Recipients of Unrelated Donor Allogeneic Transplants.

Scott R. Solomon, MD, Asad Bashey, MD PhD, Lawrence E. Morris, Karen L Manion, H. Kent Holland, MD
Journal: Blood
Blood (2009) 114 (22): 2272.
https://doi.org/10.1182/blood.V114.22.2272.2272
Published: 2009
Journal Articles

Cryopreserved G-CSF Mobilized Donor Lymphocyte Infusion (DLI) without Withdrawal of Immunosuppression Is Safe and Highly Effective for Treating Isolated Poor Donor T-cell Chimerism Following Reduced Intensity Allogeneic Transplantation (RICT).

Asad Bashey, MD, PhD, Karen L Manion, Pauline Smith, Joan Mccollum, MT, H. Kent Holland, MD, Lawrence E. Morris, Scott R. Solomon, MD
Journal: Blood
Blood (2009) 114 (22): 3308.
https://doi.org/10.1182/blood.V114.22.3308.3308
Published: 2009
Journal Articles

Outpatient Myeloablative Allogeneic Stem Cell Transplantion: A Comprehensive Approach Yields Decreased Hospital Utilization and Low Transplant Related Mortality.

Amy M. Barreras, PharmD, BCOP, Rebekah H. Matthews, PharmD, Karen L. Manion, RN, Kathy McNatt, RN, Lawrence E. Morris, MD, Asad Bashey, MD, PhD, H. Kent Holland, MD, Scott R. Solomon, MD
Journal: Blood
Blood (2006) 108 (11): 600.
https://doi.org/10.1182/blood.V108.11.600.600
Published: 2006